247 related articles for article (PubMed ID: 24746410)
1. Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs.
Beloqui A; Solinís MÁ; des Rieux A; Préat V; Rodríguez-Gascón A
Int J Pharm; 2014 Jul; 468(1-2):105-11. PubMed ID: 24746410
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier.
Beloqui A; Solinís MÁ; Gascón AR; del Pozo-Rodríguez A; des Rieux A; Préat V
J Control Release; 2013 Mar; 166(2):115-23. PubMed ID: 23266764
[TBL] [Abstract][Full Text] [Related]
3. Charge converting nanostructured lipid carriers containing a cell-penetrating peptide for enhanced cellular uptake.
Knoll P; Hörmann N; Nguyen Le NM; Wibel R; Gust R; Bernkop-Schnürch A
J Colloid Interface Sci; 2022 Dec; 628(Pt A):463-475. PubMed ID: 35932682
[TBL] [Abstract][Full Text] [Related]
4. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery.
Li H; Chen M; Su Z; Sun M; Ping Q
Int J Pharm; 2016 Sep; 511(1):524-537. PubMed ID: 27452421
[TBL] [Abstract][Full Text] [Related]
5. The interaction of protamine nanocapsules with the intestinal epithelium: A mechanistic approach.
Thwala LN; Beloqui A; Csaba NS; González-Touceda D; Tovar S; Dieguez C; Alonso MJ; Préat V
J Control Release; 2016 Dec; 243():109-120. PubMed ID: 27720993
[TBL] [Abstract][Full Text] [Related]
6. Development of an advanced intestinal in vitro triple culture permeability model to study transport of nanoparticles.
Schimpel C; Teubl B; Absenger M; Meindl C; Fröhlich E; Leitinger G; Zimmer A; Roblegg E
Mol Pharm; 2014 Mar; 11(3):808-18. PubMed ID: 24502507
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of CSK-DEX-PLGA Nanoparticles for the Oral Delivery of Exenatide to Improve Its Mucus Penetration and Intestinal Absorption.
Song Y; Shi Y; Zhang L; Hu H; Zhang C; Yin M; Chu L; Yan X; Zhao M; Zhang X; Mu H; Sun K
Mol Pharm; 2019 Feb; 16(2):518-532. PubMed ID: 30601014
[TBL] [Abstract][Full Text] [Related]
8. Oral delivery system for low molecular weight protamine-dextran-poly(lactic-co-glycolic acid) carrying exenatide to overcome the mucus barrier and improve intestinal targeting efficiency.
Song Y; Shi Y; Zhang L; Hu H; Zhang C; Yin M; Zhang X; Sun K
Nanomedicine (Lond); 2019 Apr; 14(8):989-1009. PubMed ID: 31088322
[No Abstract] [Full Text] [Related]
9. Solid lipid nanocarriers diffuse effectively through mucus and enter intestinal cells - but where is my peptide?
Dumont C; Beloqui A; Miolane C; Bourgeois S; Préat V; Fessi H; Jannin V
Int J Pharm; 2020 Aug; 586():119581. PubMed ID: 32603838
[TBL] [Abstract][Full Text] [Related]
10. Nanoarchitectonics of Layer-by-Layer (LbL) coated nanostructured lipid carriers (NLCs) for Enzyme-Triggered charge reversal.
Akkuş-Dağdeviren ZB; Fürst A; David Friedl J; Tribus M; Bernkop-Schnürch A
J Colloid Interface Sci; 2023 Jan; 629(Pt A):541-553. PubMed ID: 36088699
[TBL] [Abstract][Full Text] [Related]
11. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.
Hilgendorf C; Spahn-Langguth H; Regårdh CG; Lipka E; Amidon GL; Langguth P
J Pharm Sci; 2000 Jan; 89(1):63-75. PubMed ID: 10664539
[TBL] [Abstract][Full Text] [Related]
12. Cationic solid lipid nanoparticles with cholesterol-mediated surface layer for transporting saquinavir to the brain.
Kuo YC; Wang CC
Biotechnol Prog; 2014; 30(1):198-206. PubMed ID: 24167123
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of drug permeation under fed state conditions using mucus-covered Caco-2 cell epithelium.
Birch D; Diedrichsen RG; Christophersen PC; Mu H; Nielsen HM
Eur J Pharm Sci; 2018 Jun; 118():144-153. PubMed ID: 29524592
[TBL] [Abstract][Full Text] [Related]
14. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles.
Kuo YC; Su FL
Int J Pharm; 2007 Aug; 340(1-2):143-52. PubMed ID: 17418986
[TBL] [Abstract][Full Text] [Related]
15. Cysteine-Functionalized Nanostructured Lipid Carriers for Oral Delivery of Docetaxel: A Permeability and Pharmacokinetic Study.
Fang G; Tang B; Chao Y; Xu H; Gou J; Zhang Y; Xu H; Tang X
Mol Pharm; 2015 Jul; 12(7):2384-95. PubMed ID: 25974386
[TBL] [Abstract][Full Text] [Related]
16. A tunable Caco-2/HT29-MTX co-culture model mimicking variable permeabilities of the human intestine obtained by an original seeding procedure.
Béduneau A; Tempesta C; Fimbel S; Pellequer Y; Jannin V; Demarne F; Lamprecht A
Eur J Pharm Biopharm; 2014 Jul; 87(2):290-8. PubMed ID: 24704198
[TBL] [Abstract][Full Text] [Related]
17. HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer.
Pontier C; Pachot J; Botham R; Lenfant B; Arnaud P
J Pharm Sci; 2001 Oct; 90(10):1608-19. PubMed ID: 11745719
[TBL] [Abstract][Full Text] [Related]
18. Property profiling of biosimilar mucus in a novel mucus-containing in vitro model for assessment of intestinal drug absorption.
Boegh M; Baldursdóttir SG; Müllertz A; Nielsen HM
Eur J Pharm Biopharm; 2014 Jul; 87(2):227-35. PubMed ID: 24413146
[TBL] [Abstract][Full Text] [Related]
19. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration.
Gaba B; Fazil M; Ali A; Baboota S; Sahni JK; Ali J
Drug Deliv; 2015; 22(6):691-700. PubMed ID: 24670099
[TBL] [Abstract][Full Text] [Related]
20. SEDDS for intestinal absorption of insulin: Application of Caco-2 and Caco-2/HT29 co-culture monolayers and intra-jejunal instillation in rats.
Liu J; Werner U; Funke M; Besenius M; Saaby L; Fanø M; Mu H; Müllertz A
Int J Pharm; 2019 Apr; 560():377-384. PubMed ID: 30790612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
